WE1 —  Wednesday Session 1   (29-Jun-22   09:00—10:30)
Chair: U. Weinrich, GSI, Darmstadt, Germany
Paper Title Page
Status of the FAIR Facility  
  • P.J. Spiller
    GSI, Darmstadt, Germany
  The speaker did not provide an abstract.  
slides icon Slides WE1I2 [8.954 MB]  
Cite • reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)  
WE1I3 FRIB Commissioning 118
  • P.N. Ostroumov, F. Casagrande, K. Fukushima, K. Hwang, M. Ikegami, T. Kanemura, S.H. Kim, S.M. Lidia, G. Machicoane, T. Maruta, D.G. Morris, A.S. Plastun, H.T. Ren, J. Wei, T. Xu, T. Zhang, Q. Zhao, S. Zhao
    FRIB, East Lansing, Michigan, USA
  Funding: Work supported by the U.S. Department of Energy Office of Science under Cooperative Agreement DE-SC0000661, the State of Michigan and Michigan State University.
The Facility for Rare Isotope Beams (FRIB), a major nuclear physics facility for research with fast, stopped and reaccelerated rare isotope beams, was successfully commissioned and is in operation. The acceleration of Xe, Kr, and Ar ion beams above 210 MeV/u using all 46 cryomodules with 324 superconducting cavities was demonstrated. Several key technologies were successful-ly developed and implemented for the world’s highest energy continuous wave heavy ion beams, such as full-scale cryogenics and superconducting radiofrequency resonator system, stripping of heavy ions with a thin liquid lithium film, and simultaneous acceleration of multiple-charge-state heavy ion beams. In December 2021, we demonstrated the production and identification of 84Se isotopes and, in January 2022, commissioned the FRIB fragment separator by delivering a 210 MeV/u argon beam to the separator’s focal plane. The first two user experiments with primary 48Ca and 82Se beams have been successfully conducted in May-June 2022.
slides icon Slides WE1I3 [6.543 MB]  
DOI • reference for this paper ※ https://doi.org/10.18429/JACoW-HIAT2022-WE1I3  
About • Received ※ 21 June 2022 — Revised ※ 29 June 2022 — Accepted ※ 10 August 2022 — Issue date ※ 29 September 2022
Cite • reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)  
Innovation Aspects in Future Accelerators for Hadron Therapy  
  • E. Benedetto
    SEEIIST, Geneva, Switzerland
  • M. Vretenar
    CERN, Meyrin, Switzerland
  Funding: This work is partially supported by the European Union H2020 research and innovation programme under GA 101008548 (HITRIplus).
Modern accelerators for hadron therapy need to provide high intensity beams for innovative dose-delivery modalities such as FLASH, pencil beams for 3D scanning, as well as multiple ions for profiting of their different radio-biological properties. They need to be compact, cheap and have a reduced energy footprint. At the same time, they need to be reliable, robust and simple to operate. Cyclotrons (and compact synchrotrons) are nowadays the standard for proton therapy. For heavier ions such as carbon, synchrotrons remain the most viable option, together with the development of full-linac and FFA solutions. Concerning medical synchrotrons, new European initiatives study the feasibility of advanced multi-turn injection (including a new linac dimensioned to produce medical radioisoptopes in parallel) and advanced extraction modalities. Moreover, an innovative synchrotron for carbon ions, equipped with superconducting magnets, and a compact synchrotron optimized for helium ions, making use of proven normal-conducting technology, are being designed.
slides icon Slides WE1I4 [13.838 MB]  
Cite • reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)